The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Han Yaling - One of the best experts on this subject based on the ideXlab platform.
-
ASSA14-07-02 Comparision of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac function in patients with chronic congestive heart failure
Heart, 2014Co-Authors: Zhang Quan-yu, X Feng-qi, R Jing-jing, Deng Jie, Wang Xiaozeng, Han YalingAbstract:Background To investigate the effect of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac in chronic congestive heart failure patients. Methods 182 patients with clinical data, who suffered with chronic congestive heart failure were collected, and 67 cases were excluded. The patients were divided into 2 groups according to the different types of dosage forms: Metoprolol succinate sustained-release tablets group and Metoprolol Tartrate Tablets group. Patients in Metoprolol Tartrate Tablets group took 25 mg-50 mg Metoprolol Tartrate Tablets every day, while patients in the other group took 23.75–95 mg Metoprolol succinate sustained-release tablets every day. Average heart rate, LVDd, EF, BUN and Crea were measured. Results Compared with Metoprolol Tartrate Tablets, Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients (64.0 ± 5.4 vs 69.5 ± 7.6, p Conclusions Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients compared with Metoprolol Tartrate Tablets. The effect on cardiac and renal function was equal.
Zhang Quan-yu - One of the best experts on this subject based on the ideXlab platform.
-
ASSA14-07-02 Comparision of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac function in patients with chronic congestive heart failure
Heart, 2014Co-Authors: Zhang Quan-yu, X Feng-qi, R Jing-jing, Deng Jie, Wang Xiaozeng, Han YalingAbstract:Background To investigate the effect of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac in chronic congestive heart failure patients. Methods 182 patients with clinical data, who suffered with chronic congestive heart failure were collected, and 67 cases were excluded. The patients were divided into 2 groups according to the different types of dosage forms: Metoprolol succinate sustained-release tablets group and Metoprolol Tartrate Tablets group. Patients in Metoprolol Tartrate Tablets group took 25 mg-50 mg Metoprolol Tartrate Tablets every day, while patients in the other group took 23.75–95 mg Metoprolol succinate sustained-release tablets every day. Average heart rate, LVDd, EF, BUN and Crea were measured. Results Compared with Metoprolol Tartrate Tablets, Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients (64.0 ± 5.4 vs 69.5 ± 7.6, p Conclusions Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients compared with Metoprolol Tartrate Tablets. The effect on cardiac and renal function was equal.
Livio Dei Cas - One of the best experts on this subject based on the ideXlab platform.
-
differential effects of β blockers in patients with heart failure a prospective randomized double blind comparison of the long term effects of Metoprolol versus carvedilol
Circulation, 2000Co-Authors: Marco Metra, Raffaele Giubbini, Savina Nodari, E Boldi, Maria Grazia Modena, Livio Dei CasAbstract:Background—Both Metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than Metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs. Methods and Results—We randomized 150 patients with heart failure (left ventricular ejection fraction ≤0.35) to double-blind treatment with either Metoprolol or carvedilol. When compared with Metoprolol (124±55 mg/d), patients treated with carvedilol (49±18 mg/d) showed larger increases in left ventricular ejection fraction at rest (+10.9±11.0 versus +7.2±7.7 U, P=0.038) and in left ventricular stroke volume and stroke work during exercise (both P<0.05) after 13 to 15 months of treatment. In addition, carvedilol produced greater decreases in mean pulmonary artery pressure and pulmonary wedge pressure, both at rest and during exercise, than Metoprolol (all P<0.05). In contrast, the Metoprolol gr...
Marco Metra - One of the best experts on this subject based on the ideXlab platform.
-
carvedilol protects better against vascular events than Metoprolol in heart failure results from comet
Journal of the American College of Cardiology, 2007Co-Authors: Willem J Remme, Christian Torppedersen, John G F Cleland, Philip A Poolewilson, Marco Metra, Michel Komajda, Karl Swedberg, Andrea Di Lenarda, Phillip Spark, Armin ScherhagAbstract:Objectives We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with Metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study. Background Full adrenergic blockade by carvedilol and additional (e.g., antioxidative) properties may lead to vascular protection relative to beta-1 blockade alone, and contribute to its efficacy in HF treatment. Methods Three thousand twenty-nine patients with HF due to ischemic (51%) or idiopathic cardiomyopathy (44%) were randomized double-blind to carvedilol (n = 1,511) or Metoprolol (n = 1,518) and followed for 58 months. Vascular end points were cardiovascular death, stroke, stroke death, myocardial infarction (MI), and unstable angina. Results The effect of carvedilol on cardiovascular death improved consistently in subgroups with prespecified baseline variables. Myocardial infarctions were reported in 69 carvedilol and 94 Metoprolol patients (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.52 to 0.97, p = 0.03). Cardiovascular death or nonfatal MI combined were reduced by 19% in carvedilol (HR 0.81, 95% CI 0.72 to 0.92, p = 0.0009 vs. Metoprolol). Unstable angina was reported as an adverse event in 56 carvedilol and in 77 Metoprolol patients (HR 0.71, 95% CI 0.501 to 0.998, p = 0.049). A stroke occurred in 65 carvedilol and 80 Metoprolol patients (HR 0.79, 95% CI 0.57 to 1.10). Stroke or MI combined occurred in 130 carvedilol and 168 Metoprolol patients (HR 0.75, 95% CI 0.60 to 0.95, p = 0.015), and fatal MI or fatal stroke occurred in 34 carvedilol and in 72 Metoprolol patients (HR 0.46, 95% CI 0.31 to 0.69, p = 0.0002). Death after a nonfatal MI or stroke occurred in 61 of 124 carvedilol and in 106 of 160 Metoprolol patients (HR 0.66, 95% CI 0.48 to 0.90, p = 0.0086). Conclusions Carvedilol improves vascular outcomes better than Metoprolol. These results suggest a ubiquitous protective effect of carvedilol against major vascular events.
-
differential effects of β blockers in patients with heart failure a prospective randomized double blind comparison of the long term effects of Metoprolol versus carvedilol
Circulation, 2000Co-Authors: Marco Metra, Raffaele Giubbini, Savina Nodari, E Boldi, Maria Grazia Modena, Livio Dei CasAbstract:Background—Both Metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than Metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs. Methods and Results—We randomized 150 patients with heart failure (left ventricular ejection fraction ≤0.35) to double-blind treatment with either Metoprolol or carvedilol. When compared with Metoprolol (124±55 mg/d), patients treated with carvedilol (49±18 mg/d) showed larger increases in left ventricular ejection fraction at rest (+10.9±11.0 versus +7.2±7.7 U, P=0.038) and in left ventricular stroke volume and stroke work during exercise (both P<0.05) after 13 to 15 months of treatment. In addition, carvedilol produced greater decreases in mean pulmonary artery pressure and pulmonary wedge pressure, both at rest and during exercise, than Metoprolol (all P<0.05). In contrast, the Metoprolol gr...
X Feng-qi - One of the best experts on this subject based on the ideXlab platform.
-
ASSA14-07-02 Comparision of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac function in patients with chronic congestive heart failure
Heart, 2014Co-Authors: Zhang Quan-yu, X Feng-qi, R Jing-jing, Deng Jie, Wang Xiaozeng, Han YalingAbstract:Background To investigate the effect of Metoprolol succinate sustained-release tablets and Metoprolol tartrate tablets on cardiac in chronic congestive heart failure patients. Methods 182 patients with clinical data, who suffered with chronic congestive heart failure were collected, and 67 cases were excluded. The patients were divided into 2 groups according to the different types of dosage forms: Metoprolol succinate sustained-release tablets group and Metoprolol Tartrate Tablets group. Patients in Metoprolol Tartrate Tablets group took 25 mg-50 mg Metoprolol Tartrate Tablets every day, while patients in the other group took 23.75–95 mg Metoprolol succinate sustained-release tablets every day. Average heart rate, LVDd, EF, BUN and Crea were measured. Results Compared with Metoprolol Tartrate Tablets, Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients (64.0 ± 5.4 vs 69.5 ± 7.6, p Conclusions Metoprolol succinate sustained-release tablets decreased average heart rate in chronic congestive heart failure patients compared with Metoprolol Tartrate Tablets. The effect on cardiac and renal function was equal.
